New Therapies of Liver Diseases

• Autres auteurs: Toniutto, Pierluigi (Éditeur intellectuel)
• Format: Électronique Chapitre de livre
• Langue: anglais
• Publié: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
• Sujets: Public health & preventive medicine; tolvaptan; cirrhotic ascites; survival rate; furosemide; primary biliary cholangitis; autoantibodies; ursodeoxycholic acid; treatment response; second line therapy; primary biliary cholangitis (PBC); primary sclerosing cholangitis (PSC); clinical trials; ursodeoxycholic acid (UDCA); Farnesoid X Receptor (FXR) agonist; Pan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists; liver cancer; systemic treatment; immunotherapy; real-world; unresectable hepatocellular carcinoma; cirrhosis; decompensation; bleeding; varices; survival; infection; alcoholic hepatitis; acute-on-chronic liver failure; cholangiocarcinoma; colorectal cancer metastases; hepatocellular carcinoma; liver transplantation; Milan criteria; alpha-fetoprotein; solid organ transplantation; liver injury; immunosuppressant; SARS-CoV-2; humoral response; vaccination; portal-systemic shunt; ammonia; vigilance; HBV; HDV; antivirals; functional cure; pharmacology; acute-on-chronic liver failure (ACLF); liver transplantation (LT); decompensated cirrhosis; portal hypertension; ascites; non-selective beta-blockers; TIPS; rifaximin; human albumin; statins; targeted therapy; effective hypovolemia; anti-mineralocorticoids; loop diuretics; vaptans; n/a
• Accès en ligne: DOAB: download the publication; DOAB: description of the publication

In this Special Issue of the journal, advancements in the treatment of liver diseases are illustrated by international experts in the field. New treatment options for primary biliary cirrhosis and, hopefully, primary sclerosing cholangitis are discussed. Up-to-date pharmacological therapy for preven...